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Objectives The aim of this study was to comprehensively delineate iron metabolism and its implications in patients with
chronic heart failure (CHF).
Background Iron deficiency is an emerging therapeutic target in CHF.
Methods Iron and clinical indexes were quantified in 157 patients with CHF.
Results Several observations were made. First, iron homeostasis was deranged in anemic and nonanemic subjects and
characterized by diminished circulating (transferrin saturation) and functional (mean cell hemoglobin concentra-
tion) iron status in the face of seemingly adequate stores (ferritin). Second, while iron overload and elevated iron
stores were rare (1%), iron deficiency (transferrin saturation 20%) was evident in 43% of patients. Third, disor-
dered iron homeostasis related closely to worsening inflammation and disease severity and strongly predicted
lower hemoglobin levels independently of age, sex, erythrocyte sedimentation rate, New York Heart Association
(NYHA) functional class, and creatinine. Fourth, the etiologies of anemia varied with disease severity, with an
iron-deficient substrate (anemia of chronic disease and/or iron-deficiency anemia) evident in 16%, 72%, and
100% of anemic NYHA functional class I or II, III, and IV patients, respectively. Although anemia of chronic dis-
ease was more prevalent than iron-deficiency anemia, both conditions coexisted in 17% of subjects. Fifth, iron
deficiency was associated with lower peak oxygen consumption and higher ratios of ventilation to carbon dioxide
production and identified those at enhanced risk for death (hazard ratio: 3.38; 95% confidence interval: 1.48 to
7.72; p  0.004) independently of hemoglobin. Nonanemic iron-deficient patients had a 2-fold greater risk for
death than anemic iron-replete subjects.
Conclusions Disordered iron homeostasis in patients with CHF relates to impaired exercise capacity and survival and appears
prognostically more ominous than anemia. (J Am Coll Cardiol 2011;58:1241–51) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.040Despite optimal conventional therapy, many patients with
chronic heart failure (CHF) remain symptom limited,
exercise intolerant, and subject to high rates of mortality.
See page 1252
The persistence of such poor outcomes suggests that addi-
tional adverse phenomena remain unmitigated by current
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accepted April 19, 2011.therapeutic strategies and endure to accelerate disease
progression.
Systemic iron homeostasis is frequently deranged in
chronic disorders (1–5), but the integrity of iron metab-
olism in CHF is poorly characterized. Prior analyses are
sparse and have largely been conducted in anemia pa-
tients (6,7) or based solely on serum iron and ferritin
concentrations (8 –10). However, total body iron is dis-
tributed across circulating, functional, and storage iron
compartments that can be perturbed independently of
one another (11–13). Because iron indexes typically
reflect individual compartments and are influenced by
factors other than iron status, multiple markers are
generally needed to adequately gauge iron homeostasis
(11,12). To date, no study has comprehensively delin-
eated iron metabolism in anemic and nonanemic patients
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ported prevalence estimates for
the full spectrum of iron disor-
ders. Moreover, the diagnostic
utility of iron markers in anemic
patients with CHF has so far
been poorly explored.
Iron is obligatory for optimal
erythrocyte production, and iron-
deficient erythropoiesis (IDE) due
to defectively mobilized (func-
tional deficiency  anemia of
chronic disease [ACD]) and/or
depleted (absolute deficiency 
iron deficiency anemia [IDA])
stores is the most common cause
of anemia globally (14–17). How-
ever, despite the high burden and
adverse implications of anemia in
CHF patients (18), the use of con-
ventional iron indexes to distin-
guish ACD from IDA and to
identify IDA in the midst of ACD
(ACD  IDA) has not been re-
ported. Additionally, it is unclear
whether the etiologies of anemia
vary with disease severity or
whether iron deficiency has conse-
quences in CHF besides anemia.
Iron is quantitatively the most
important biocatalyst in human
physiology, with critical roles
beyond hemoglobin synthesis
(19–25). Even in the absence of
anemia, iron deficiency is a potent substrate for dyspnea and
exercise intolerance (26,27) and identifies those in the
general population at a heightened risk for mortality (28). In
patients with uremia, lower levels of transferrin saturation
(TSAT), a more reliable marker of iron deprivation than
ferritin in inflammatory cohorts, also correlate to poorer
survival (29). Whether lower TSAT relates to mortality
independently and more powerfully than anemia in CHF
remains unclear.
In a broad spectrum of patients with systolic CHF, we
sought to characterize: 1) iron metabolism and its predic-
tors; 2) the prevalence of the full spectrum of iron disorders,
with an emphasis on discriminating between ACD, IDA,
and ACD  IDA; 3) variations in the etiologies of anemia
with New York Heart Association (NYHA) functional
class; and 4) the relation of iron deficiency to exercise
performance and survival.
Methods
Study population. We prospectively appraised clinical and
Abbreviations
and Acronyms
ACD  anemia of chronic
disease
CHF  chronic heart failure
CI  confidence interval
CRP  C-reactive protein
ESR  erythrocyte
sedimentation rate
FERRIC-HF  Ferric Iron
Sucrose in Heart Failure
HR  hazard ratio
IDA  iron deficiency
anemia
IDE  iron-deficient
erythropoiesis
IQR  interquartile range
MCHC  mean cell
hemoglobin concentration
NYHA  New York Heart
Association
%HRC  percent
hypochromic red cells
sTFR  soluble transferrin
receptor
TIBC  total iron-binding
capacity
TSAT  transferrin
saturation
VCO2  carbon dioxide
production
VE  minute ventilationiron indexes in 157 consecutively eligible patients with CHFwho attended dedicated heart failure clinics and wards at
Wexham Park Hospital (Slough, United Kingdom) and the
Royal Brompton Hospital (London, United Kingdom).
Control subjects (n  22) with no known medical problems
or regular medications were also recruited. The diagnosis of
CHF was based on a 6-month history of appropriate
symptoms and signs and a left ventricular ejection fraction
45%. Patients with recent myocardial infarctions, those
with ongoing non-CHF inflammatory processes, and those
using iron, erythropoietic, immunomodulatory, or renal
replacement therapies within 3 months of recruitment were
excluded. Informed consent was obtained from all subjects,
and the local ethics and research governance committees at
both institutions approved the study.
Laboratory measurements. Peripheral venous blood sam-
ples were obtained in the morning from all participants. Full
blood counts were measured from K3 ethylenediaminetet-
raacetic acid samples initially using a Coulter S-Plus Jr.
electronic counter (Coulter Electronics, High Wycombe,
United Kingdom) at Wexham Park and an ADVIA 120
analyzer (Bayer Diagnostics, Berkshire, United Kingdom)
at Royal Brompton. Because of contractual issues, the
ADVIA 120 was substituted by a Coulter S-Plus Jr. counter
halfway through the study. Percent hypochromic red cells
(%HRC) and red cell distribution width were assayed flow
cytometrically using the ADVIA 120. Serum iron and total
iron-binding capacity (TIBC) were measured colorimetri-
cally (Alpkem RFA analyzer, Alpkem Corporation, Clacka-
mas, Oregon). TSAT was calculated as 100  serum
iron/TIBC. Serum ferritin was determined using a Cobas
Core analyzer (Roche Diagnostics GmbH, Mannheim,
Germany). For soluble transferrin receptor (sTFR) concen-
trations, sera were spun (3,000 rpm for 15 min), separated,
and stored immediately at 80°C for later quantification
using an enzyme-linked immunosorbent assay (Dade Beh-
ring GmbH, Marburg, Germany) with a sensitivity of 0.3
pg/ml. All other biochemical tests were performed using
standard techniques.
Definitions of anemia and iron deficiency. Anemia was
defined as hemoglobin 13 g/dl in men and 12 g/dl in
women (30). Iron deficiency was principally defined as
TSAT 20% because TSAT is a more reliable marker of
iron status than ferritin during inflammation (12,31,32),
and diminished circulating iron status is a feature of both
absolute (TSAT20%, low ferritin) and functional (TSAT
20%, normal or high ferritin) iron deficiency. Because
ferritin overestimates iron stores in inflammatory cohorts
(32,33) prevalence estimates for absolute and functional iron
deficiency are given using conventional (30 g/l) (1,12) and
pragmatic (100 g/l) (34,35) cutoffs.
Prevalence of distinct iron disorders and the origins of
anemia. To estimate the prevalence of distinct iron disor-
ders and to discriminate the cause(s) of anemia, we adopted
a multiple-measures approach based on TSAT, ferritin, and
TIBC or sTFR. Patients with anemia with TSAT 20%
had pure IDA if ferritin levels were 30 g/l (1,12).
b
t
o
m
V
d
S
f
I
P
1
s
K
v
r
f
p
s
c
l
v
C
(
a
n
h
e
a
s
i
a
l
e
t
p
f
O
u
w
t
d
w
a
B
s
c
R
B
w
l
I
(
r
a
t
a
b
A
5
t
1243JACC Vol. 58, No. 12, 2011 Okonko et al.
September 13, 2011:1241–51 Iron Homeostasis in Heart FailureFerritin levels 30 g/l identified those with ACD with or
without coexistent IDA (1). Because TIBC and sTFR
concentrations are augmented by iron store depletion but
not by inflammation (11,12,36), their elevated levels were
used to identify patients with ACD and concomitant IDA.
Two multiple-measures models were constructed. The first
used only clinically available indexes (TSAT, ferritin, and
TIBC) and was therefore termed the clinical model. The
second used TSAT, ferritin, and sTFR and was termed the
research model, because sTFR assays are principally re-
search tools. The research model served to validate the
results of the clinical model in anemic subjects.
Cardiopulmonary exercise testing. Patients underwent a
modified Naughton (37) symptom-limited treadmill exer-
cise test. Minute ventilation (VE), oxygen consumption,
and carbon dioxide production (Vco2) were monitored on a
reath-by-breath basis using a respiratory mass spectrome-
er (Amis 2000; Innovision, Copenhagen, Denmark). Peak
xygen consumption adjusted for body weight (milliters per
inute per kilogram) and the slope of the relation between
E and Vco2 (VE/Vco2) were calculated as previously
escribed (37).
tatistical analysis. Data are presented as mean  SD,
requency (percent), or median (interquartile range [IQR]).
ntergroup comparisons were made using Student t test,
earson chi-square test, the Mann-Whitney U test,
-way analysis of variance with Fisher protected least
ignificant difference post hoc testing, or nonparametric
ruskal-Wallis analysis of variance as appropriate. To
alidate TSAT 20% as a marker of iron deficiency,
eceiver-operating characteristics curve analysis was per-
ormed to determine which TSAT or ferritin cutoffs
rovided optimal sensitivity and specificity for predicting
TFR levels 1.76 mg/l (best noninvasive marker of
ellular iron deprivation) (12,36).
Relations between variables were assessed by multiple
inear regression using age, sex, ethnicity, CHF etiology, left
entricular ejection fraction, NYHA functional class,
-reactive protein (CRP), erythrocyte sedimentation rate
ESR), creatinine, platelet counts, beta-blocker use, and
ntiplatelet or anticoagulant drug use as covariates. Prog-
ostic associations were determined using Cox proportional-
azards analyses (univariate, bivariate, and trivariate mod-
ls) only for covariates that were available in all patients. To
ssess the interaction between iron deficiency and anemia on
urvival, patients were stratified into 4 groups (nonanemic
ron-replete, anemic iron-replete, nonanemic iron-deficient,
nd anemic iron-deficient). Kaplan-Meier curves for cumu-
ative survival were constructed for each group and differ-
nces in survival rates tested using the Cox-Mantel log-rank
est. All-cause mortality status was obtained from direct
hysical or telephone contact with patients or their relatives,
rom the hospital information systems, and from the U.K.
ffice of National Statistics. No patient was lost to follow-
p, and the minimum duration of follow-up for all survivors
as 1.4 years.Data were missing for certain indexes, with no imputa-
ion performed. Sensitivity analyses revealed no significant
ifference in baseline characteristics between those who
ere and were not quantified for each index. Data were
nalyzed using StatView version 4.5 (Abacus Concepts Inc.,
erkeley, California). A p value 0.05 was considered
tatistically significant, without adjustment for multiple
omparisons.
esults
aseline characteristics. Patients were similar to controls
ith respect to age, sex, and ethnicity, but had significantly
ower hemoglobin and higher creatinine levels (Table 1).
ron deficiency (TSAT 20%) was evident in 68 patients
43%). Iron-deficient patients did not differ from iron-
eplete subjects with respect to antiplatelet (p  0.92) or
nticoagulant (p  0.17) drug use or platelet counts, but
hey had higher NYHA functional class designations, CRP,
nd white cell counts, and lower hemoglobin and beta-
locker use.
bnormal iron metabolism in CHF. DIMINISHED CIRCU-
LATING IRON STATUS. Male (22.9  9.5%) and female
(20.4 10.4%) patients had similar TSAT (p 0.15) (Fig. 1A).
Compared with controls, patients with CHF exhibited
lower TSAT and serum iron and higher TIBC and sTFR
levels (Table 2). Circulating deficits worsened with NYHA
functional class and were greater in patients with anemia
(Fig. 2A).
ATTENUATED FUNCTIONAL IRON STATUS. The mean cell
hemoglobin concentration (MCHC) was higher in male
(33.1  1.1 g/dl) than in female (32.4  1.5 g/dl) patients
(p  0.005) (Fig. 1B). Compared with controls, patients
with CHF exhibited reductions in MCHC and hemoglobin
and increases in %HRC and red cell distribution widths
(Table 2). Functional deficits worsened with NYHA func-
tional class and were more marked in patients with anemia
(Fig. 2B).
SEEMINGLY PRESERVED STORAGE IRON STATUS. Median
ferritin levels were higher in male (144 g/l; IQR: 48 to 193
g/l) than female (88.9 g/l; IQR: 29 to 118 g/l) patients
(p  0.01) (Fig. 1C). On comparing all patients with CHF
with controls, no significant difference in ferritin or sTFR/
log ferritin ratio was found. However, on stratifying for
NYHA functional class, there was a progressive decline in
ferritin levels from patients in class I or II (101 g/l; IQR:
4 to 216 g/l) to controls (85 g/l; IQR: 47 to 137 g/l)
o patients in class III (70 g/l; IQR: 40 to 123 g/l) and
then patients in class IV (59 g/l; IQR: 21 to 121 g/l;
analysis-of-variance p  0.04). Similarly, the sTFR/log
ferritin ratio progressively increased from controls to pa-
tients in NYHA functional class I or II, class III, and then
class IV (p  0.05) (Fig. 2C).
Predictors of impaired iron homeostasis. For the circu-
lating iron pool, higher CRP and NYHA functional class
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 0.0012), and non-Caucasian ethnicity, higher NYHA
unctional class, and lower beta-blocker use predicted higher
TFR (r2  0.5, p  0.0002). For the functional pool, only
igher age and NYHA functional class remained correlated
ith lower MCHC (r2  0.18, p  0.0001), and non-
Caucasian ethnicity and higher NYHA functional class
(r2  0.42, p  0.0001) predicted higher %HRC. For iron
stores, non-Caucasian ethnicity, female sex, and higher
NYHA functional class were related to lower ferritin (r2 
0.42, p  0.0001), and higher NYHA functional class and
non-Caucasian ethnicity predicted higher sTFR/log ferritin
ratio (r2  0.55, p  0.0001).
revalence of iron disorders. Receiver-operating charac-
eristic curve analysis confirmed that TSAT (area under the
urve 0.72, p 0.002), but not ferritin (area under the curve
.59, p  0.28), predicted sTFR 1.76 mg/l and that a
utoff of 20% was optimal. Consequently, iron deficiency
TSAT 20%) was evident in 43%, 64%, and 30% of all,
nemic, and nonanemic patients, respectively. Using a
erritin cutoff of 30 g/l, functional iron deficiency was
Baseline CharacteristicsTable 1 Baseline Characteristics
Variable
Control Subjects
(n  22)
Age (yrs) 66 9
Men 68%
Caucasian 82%
Ischemic cause —
NYHA functional class —
I/II —
III —
IV —
LVEF (%) —
Creatinine (mol/l) 86 21
ESR (mm/h)‡ 8 6
CRP (mg/l)‡ 6 (5–7)
Hemoglobin (g/dl) 14.6 1.3
Mean cell volume (fl) 90 4
Mean cell hemoglobin (pg) 30 1
MCHC (g/dl) 34.1 1.1
White cell count (109/l) 6.8 1.4
Platelet count (109/l) 228 49
Vitamin B12 (pmol/l) 375 234
Red cell folate (g/l) 349 122
Treatment
ACE inhibitors or ARBs —
Beta-blockers —
Diuretic agents —
Aspirin —
Warfarin —
Values are mean  SD, proportions (%), or median (interquartile rang
with TSAT 20%. †p  0.01 for comparisons between patients with C
and 14 iron-deficient patients. CRP was measured in 20 controls, 51
ACE  angiotensin-converting enzyme; ARB  angiotensin recept
erythrocyte sedimentation rate; LVEF  left ventricular ejection fracti
Association; TSAT  transferrin saturation.vident in 31%, 44%, and 22% of all, anemic, and nonane-ic patients, respectively. Using a cutoff of 100 g/l, it
as present in 14%, 23%, and 8% of all, anemic, and
onanemic patients, respectively.
Using the FERRIC-HF (Ferric Iron Sucrose in Heart
ailure) criteria (ferritin 100 or 100 to 300 g/l with
TSAT 20%), iron deficiency was present in 69%, 78%,
and 65% of all, anemic and nonanemic patients, respec-
tively. FERRIC-HF–defined functional (ferritin 100 to 300
g/l with TSAT 20%) and absolute (ferritin 100 g/l)
eficiencies were evident in 10% and 59% of subjects,
espectively.
Using the multiple-measures clinical model, distinct di-
gnoses were possible in 131 subjects (83%) (Fig. 3). Of the
otal population, 37 (24%) had normal iron status, none had
ron overload, 57 (36%) had a nonanemic iron-deficient
tate, and 36 (23%) had an anemic iron-deficient state.
tiology of anemia in patients with CHF and its variation
ith disease severity. Anemia was present in 61 patients
39%). Lower TSAT, higher ESR, and female sex were
ndependently associated with lower hemoglobin (r2 0.47,
 0.001). Applying the multiple-measures clinical model,
Patients With CHF
All
(n  157)
TSAT >20%
(n  89)
TSAT <20%
(n  68)
71 12 70 10 72 14
72% 79% 63%*
87% 89% 84%
64% 63% 67%
2.6 0.8 2.3 0.7 3.0 0.8*
45% 66% 18%
41% 30% 54%
14% 3% 28%
32 9 34 9 30 10
22 49† 119 40 125 59
26 27 20 23 33 31
8 (6–19) 7 (6–10) 12 (7–43)*
3.1 1.7† 13.7 1.6 12.3 1.6*
91 6 92 6 89 6*
30 2 31 2 29 2*
2.9 1.3† 32.6 1.4 33.3 1.2*
7.9 3.4 7.4 1.8 8.5 4.7*
31 99 225 62 243 145
63 183 340 151 393 215
06 235† 483 191 533 278
86 88 85
61 76 42†
89 89 89
44 44 45
25 30 20
0.05 for comparisons between patients with TSAT 20% and those
controls. ‡ESR was measured in 9 controls, 20 iron-replete patients,
lete patients, and 39 iron-deficient patients.
ker; CHF  chronic heart failure; CRP  C-reactive protein; ESR 
HC  mean cell hemoglobin concentration; NYHA  New York Heart1
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Stratification on the basis of NYHA functional class re-
vealed that iron-deficient substrates (ACD and/or IDA)
were evident in 17%, 72%, and 100% of patients in classes
I or II, III, and IV, respectively, with ACD the dominant
A
B
C
Figure 1 Distribution of Iron Markers in Patients With CHF
Sex-specific distribution of markers of circulating (A), functional (B), and stor-
age (C) iron status. CHF  chronic heart failure; MCHC  mean cell hemoglo-
bin content; TSAT  transferrin saturation.etiology in each stratum (Fig. 4). The multiple-measures tresearch model was applicable to 21 patients with anemia.
Six (29%) had isolated ACD, 5 (24%) had ACD  IDA,
nd 1 (5%) had isolated IDA.
ron status and exercise performance. Twenty-seven pa-
ients underwent cardiopulmonary exercise testing. No sig-
ificant difference in baseline characteristics existed between
hose who did and did not perform exercise testing. Peak
xygen consumption was lower in iron-deficient than in
ron-replete (11.4 2.1 ml/kg/min vs. 14.9 1.7 ml/kg/min,
 0.03) patients and positively correlated to TSAT (r 
.71, p 0.0001), MCHC (r 0.63, p 0.001), and ferritin
r 0.48, p 0.01) independently of NYHA functional class
nd hemoglobin. The VE/Vco2 slope was higher in iron-
deficient than in iron-replete (54.8  10.6 vs. 44.1  9.1,
 0.02) patients and related only to TSAT (r  0.43,
p  0.03).
Iron status and survival. Over a median follow-up period
of 743 days (IQR: 304 days), 27 patients (17%) died. In
univariate analyses, increased mortality was related only to
TSAT 20% (hazard ratio [HR]: 3.38; 95% confidence
interval [CI]: 1.48 to 7.72; p  0.004), NYHA functional
lass (HR: 2.13; 95% CI: 1.28 to 3.55; p  0.004),
eta-blocker use (HR: 0.41; 95% CI: 0.19 to 0.87; p 
.02), hemoglobin (HR: 0.74; 95% CI: 0.58 to 0.93; p 0.01),
nd creatinine (HR: 1.009; 95% CI: 1.003 to 1.014; p 
.001). Survival was unrelated to TSAT as a continuous
ariable. In bivariate and trivariate prognostic models, iron
eficiency predicted mortality independently of all other
ovariates in each model.
On stratifying patients into hematological subsets, there
as a significant difference in survival among the groups
Fig. 5). Patients with IDA had a 2-fold greater risk for
eath than those with nonanemic iron deficiency and a
-fold greater risk for death than iron-replete patients with
r without anemia.
iscussion
rincipal findings. We investigated iron metabolism and
ts clinical significance in anemic and nonanemic patients
ith systolic CHF and made 3 key observations. First,
ron homeostasis was deranged in a predominately func-
ionally iron deficient manner and related closely to
YHA functional class, ethnicity, CRP, and anemia.
econd, the etiologies of anemia varied with disease
everity, with an iron-deficient substrate increasingly
vident with disease progression. Although ACD was
ore prevalent than IDA, both conditions frequently
oexisted. Third, iron deficiency (TSAT 20%) was
ssociated with exercise intolerance and exertional hyper-
entilation and identified those at an enhanced risk for
eath independently and more powerfully than anemia.
ron homeostasis in CHF. Although the existence of
ron deficiency (6 – 8,10) and potential benefits (34,35) of
orrecting it in CHF are emerging, little is known about
he appropriateness of systemic iron allocation in this
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Iron Homeostasis in Heart Failure September 13, 2011:1241–51disorder. Normally, iron principally cycles from the
circulation to the erythroid marrow to macrophages and
back to the circulation, with the flow of iron between
compartments matched to achieve equilibrium. Powerful
homeostatic mechanisms orchestrate these movements to
maintain the size of each iron pool, with the overriding
objective of ensuring that circulating levels are sufficient
to support normal erythrocyte hemoglobinization (11–13).
Here, we found that the circulating pool of iron was
contracted by 15% to 35% in patients with CHF, implying
that defects in circulatory iron influx and/or efflux existed. In
parallel, the function pool was similarly attenuated, and this
reflected the decrease in circulating iron, as the means of
iron entry into functional sites (i.e., transferrin receptors)
were adequate. In contrast, the storage compartment ap-
peared to be expanded by 24% in patients with CHF. Taken
Iron StatusTable 2 Iron Status
Variable Normal Values
C
Circulating iron status
Iron (mol/l) 9–30
9
TIBC (mol/l) 45–66
45
66
TSAT (%) 30–45
20
45
sTFR (mg/l) 1.76
1.76
n
Functional iron status
Hemoglobin (g/dl) 13 (male), 12 (female)
Mean cell volume (fl) 80–100
Mean cell hemoglobin (pg) 25–35
MCHC (g/dl) 32–36
32
Red cell distribution width (%) 11.5–14.5
n
Hypochromic cells (%) 2.5–5.0
5
n
Reticulocyte hemoglobin (pg) 27
n
Stored iron status
Ferritin (g/l) 30–300
15
30
100
300
sTFR/log ferritin 1.00
n
Values are mean  SD, proportions (%), or median (interquartile range). *p  0.05 for compariso
atients with CHF.
CHF  chronic heart failure; MCHC  mean cell hemoglobin concentration; sTFR  soluble tratogether, these data indicate that in the deranged milieu of iCHF, iron is abnormally handled, being preferentially
trafficked into storage sites and withdrawn from the circu-
lation and erythroid marrow, triggering IDE. This is evi-
dent in anemic and nonanemic subjects and mirrors abnor-
mal iron kinetics in a plethora of inflammatory disorders (1–5).
Although iron stores were biochemically enhanced in
patients with CHF compared with controls, careful
analysis of the data suggests that their progressive deple-
tion occurs with worsening disease. Serum ferritin levels
15 to 30 g/l unequivocally signify exhausted iron
eserves (1,11,33). However, as an acute phase reactant,
erritin is 3-fold higher in inflammatory cohorts than in
ormal subjects for each grade of marrow iron (32,33).
hile ferritin levels in this study were, on average, higher
n patients with CHF than controls, they progressively
eclined from patients in class I or II to controls to those
Patients With CHF
Subjects
22)
All
(n  157)
Nonanemic
(n  96)
Anemic
(n  61)
 5 14 6* 16 6 11 5†
— 18% 7% 37%
 8 64 12 64 11 64 13
— 1% 2% 0%
— 35% 23% 55%
 9 22 10* 25 10 18 8†
— 43% 30% 64%
— 3% 5% 0%
 0.3 1.7 0.8 1.7 0.9 1.7 0.6
— 29% 26% 33%
2 55 34 21
 1.3 13.1 1.7 14.2 1.1 11.3 0.9
 4 91 6 92 6 90 7†
 1 30 2 30 2 29 3†
 1.1 32.9 1.3* 33.0 1.1 32.7 1.5
— 20% 17% 25%
 0.3 14 2* 14 1 15 2†
3 40 25 15
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ns betwn class III and then those in class IV. Thus, while ferritin
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September 13, 2011:1241–51 Iron Homeostasis in Heart Failurelevels are elevated early in the course of CHF, they do not
escalate further, as would be expected if they simply
tracked inflammation, but diminish with disease severity.
Because elevated ferritin concentrations still correlate
with the degree of stainable marrow iron in inflammatory
cohorts (33), our findings suggest that a true depletion of
iron stores occurs with advancing CHF. This is consis-
tent with data from Nanas et al. (6) and is a feature of
other inflammatory conditions (2).
Predictors of impaired iron status. Disease severity, as
quantified by NYHA functional class, was a powerful and
inverse predictor of all iron compartments. Because it did so
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Figure 2 Iron Metabolism in CHF
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ANOVA  analysis of variance; MCHC  mean cell hemoglobin concentration; sTFindependently of other measured covariates, iron perturba-tions might be causally linked to CHF progression. More-
over, the fact that iron markers were related to NYHA
functional class, an index of the overall impact of the heart
failure syndrome on patients, but not to left ventricular
ejection fraction, suggests that iron abnormalities are a
consequence of CHF rather than a direct result of myocar-
dial dysfunction.
Besides NYHA functional class, non-Caucasian ethnicity
also predicted poorer global iron status. This likely reflects
the fact that the diet of Southeast Asians, who were the
predominant non-Caucasians, is typically high in phos-
phates and phytates that inhibit iron absorption (38).
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away from the circulation into stores in chronic disorders
(1,4). Importantly, we found no relation between iron
indexes and antiplatelet or anticoagulant drug use or platelet
counts, arguing against a dominant role for occult hemor-
rhage in iron derangements.
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uum, and to the best of our knowledge, this is the first study
to report prevalence estimates for the full spectrum of
anomalies in CHF. In contrast to healthy elders (39),
ron-deficient states were more common than those of iron
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enesis of iron insufficiency. Interestingly, 29 patients
15.6%) had nonanemic IDE, which can precipitate fatigue,
epression, and exercise intolerance (11,26,27). Thus, iden-
ifying IDE before the onset of anemia is important,
specially in patients with CHF, in whom evidence suggests
hat anemia is prevalent and adverse (18). Despite such
vidence, however, the relation of iron indexes to hemoglo-
in in CHF remains poorly explored.
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irect trigger of erythroid proliferation (16), an enhancer of
lobin synthesis (15), and the strongest inducer of aminole-
ulinic acid synthase, the rate-limiting enzyme of heme
roduction (14). Accordingly, lower TSAT predicted lower
emoglobin independently of higher ESR and female sex.
hat the ESR was independently predictive of hemoglobin
IDE with
depleted
stores
-30       <20         <20         <20         <20         <20
0         <30          ≥30         ≥30         ≥30         <30
-- -- -- ≤65         >65   ≥45
o           No          No          Yes         Yes     Yes
n=3               n=8              n=21             n=16 n=10             n=10
on
letion
IDE with 
normal
stores ACD ACD + IDA IDA
row) using established criteria (bottom row). Adapted from Brittenham (11).
thropoiesis; TIBC  total iron-binding capacity; TSAT  transferrin saturation.   20
    <3
      N
         
Ir
dep
iddle
ent eryikely reflects the fact that inflammation precipitates anemia
s
p
c
t
A
e
f
d
I
s
e
3
w
a
s
p
t
a
s
a
e
o
m
c
a
p
d
t
1249JACC Vol. 58, No. 12, 2011 Okonko et al.
September 13, 2011:1241–51 Iron Homeostasis in Heart Failurealso by directly suppressing erythroid cells and inducing
their resistance to erythropoietin (1). That sex was also
independently predictive may reflect the potent influence of
androgens on erythropoiesis (41).
ACD (with or without IDA) was the dominant substrate
for anemia in our cohort, evident in 44% to 53% of subjects.
This is similar to the frequencies reported in prior analyses
(7,18), concurs with experimental data (42), but supersedes
the 33% burden seen in otherwise healthy anemic elders
(43). Although less prevalent, IDA was evident in a sub-
stantial 29% to 34% of patients with anemia. This is higher
than most prior estimates (7,9,10), possibly because of our
use of TIBC and sTFR levels to identify IDA in those with
ACD.
Next, we sought, for the first time, to determine whether
the etiologies of anemia varied with CHF severity. We
found that as NYHA functional class worsened, the preva-
lence of ACD and/or IDA rose, with ACD being increas-
ingly complicated by IDA. This is consistent with the
known evolution of ACD, whereby persistent hypoferremia
ultimately impairs iron storage, giving rise to concomitant
IDA that is masked by inflammatory hyperferritemia
(1,2,44). Indeed, in an anemic NYHA functional class IV
cohort, Nanas et al. (6) found definitive IDA in 73% of
patients, whose mean ferritin level was 75 g/l. In this
tudy, only 53% of our anemic NYHA functional class IV
atients had IDA, possibly because they were healthier. In
A
Figure 5 Prognostic Association of Varying Hematological Grou
Kaplan-Meier survival curves for hematological subsets (A) with corresponding haz
TSAT  transferrin saturation.ontrast, our prevalence estimate for ACD is higher than fhat of Nanas et al. (18.9%), probably because we diagnosed
CD using positive criteria, whereas it was a diagnosis of
xclusion in that analysis. However, given their mean
erritin levels, many of the Nanas et al. (6) cohort with
efinitive IDA also likely met biochemical criteria for ACD.
ron status and its relation to exercise performance and
urvival. Iron-deficient patients were objectively more ex-
rcise intolerant and breathless on exertion and harbored a
-fold escalated risk for death irrespective of whether they
ere anemic. Indeed, iron-deficient nonanemic patients had
2-fold greater risk for mortality than iron-replete anemic
ubjects. This implies that iron deficiency per se might be
rognostically more ominous than anemia in CHF. Al-
hough lower TSAT may merely reflect other unadjusted
dverse factors, a causal prognostic role cannot be excluded.
Besides hemoglobin, iron is an obligate component of
everal metalloproteins that mediate pivotal functions, such
s myoglobin (oxygen storage) (19), electron transport
nzymes (oxidative phosphorylation) (20,21), ribonucle-
tide reductase (deoxyribonucleic acid synthesis) (22),
onoamine oxidase (neurotransmission) (23), and cy-
looxygenases (inflammation) (24). Iron is thus indispens-
ble for life, and cellular iron deprivation triggers G1/S
hase mitotic arrest and apoptosis (25). Iron deficiency also
rives catecholamine production (45) and ventricular hyper-
rophy (46), factors that bode unfavorably in CHF. Such
B
tios (HRs) and 95% confidence intervals (CIs) depicted (B).ps
ard raactors might therefore underlie the associations between
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other analyses (28,29,47).
Study implications. This study has important ramifica-
tions. First, it confirms emerging evidence that iron defi-
ciency is another pathophysiological feature of CHF that
likely arises from the syndrome itself to drive symptoms,
exercise intolerance, and mortality irrespective of anemia.
Second, it supports the routine assessment of iron status in
patients with CHF, particularly in those with refractory
symptoms, advanced disease, or anemia. Third, it suggests
that low hemoglobin levels in CHF result predominately
from true substrates and are not just spurious consequences
of hemodilution. Fourth, it shows that the rational use of 3
simple indexes (TSAT, ferritin, and TIBC) enables the
biochemically meaningful discrimination of ACD from
IDA and the identification of IDA in the midst of ACD.
Decisions regarding the mandatory (IDA and ACD 
IDA) or adjuvant (ACD) need for iron supplementation can
therefore be facilitated. Finally, it suggests that even if iron
deficiency is not causally related to mortality, its presence
might identify those in need of escalated care.
Study limitations. First, this study was observational, so
causal links between variables cannot be established. Sec-
ond, it represents data measured at a single time point and
does not inform on temporal trends in iron status or anemic
etiology. Third, for technical and logistical reasons, indexes
such as %HRC and sTFR were quantified only in subsets of
patients. However, no difference in clinical characteristics
existed between those who were and were not measured.
Fourth, brain natriuretic peptide measurements were un-
available, but the prognostic independence of iron deficiency
from brain natriuretic peptide was suggested in a prior study
(47). Fifth, we did not include patients with acute heart
failure or recent infarcts, who may have greater iron de-
rangements (6). Finally, a conventional ferritin criteria (30
g/dl) (1,12) was used to diagnose IDA, despite evidence that
higher cutoffs may be better in inflammatory cohorts. Thus,
we might have overestimated the prevalence of ACD and
underestimated that of IDA in this study. Because the
absence of stainable iron in bone marrow aspirates is the
optimal marker of iron deficiency, studies predicated on this
are needed to define “normal” ferritin levels in CHF.
However, by demonstrating that IDA remained substan-
tially prevalent despite the use of a conservative cutoff, we
contend that our study further highlights its importance in
CHF.
Conclusions
Iron metabolism is deranged in CHF and is characterized
by a diminished circulating and functional iron status in the
face of seemingly adequate stores. Disordered iron homeo-
stasis correlates to worsening inflammation, NYHA func-
tional class, and non-Caucasian ethnicity, and increasingly
underlies anemia with CHF progression. Iron deficiency, as
defined by a TSAT 20%, relates to exercise intoleranceand amplified mortality, and should be targeted in future
survival trials.
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